Lung Cancer: NSCLC...3 Background Epidemiology: Lung cancer is the leading cause of cancer-related...
Transcript of Lung Cancer: NSCLC...3 Background Epidemiology: Lung cancer is the leading cause of cancer-related...
Lung Cancer:
NSCLC(Non-small Cell Lung Cancer)
Gregory Butler, PharmD Candidate 2020MCPHS University
OBJECTIVES▹ Discuss the epidemiology, etiology, and
pathophysiology of non-small cell lung cancer (NSCLC)
▹ Review appropriate treatment options for different presentations of NSCLC
▹ Describe example maintenance therapies, monitoring, and side-effect management of NSCLC treatment
2
Background3
Epidemiology: Lung cancer is the leading cause of cancer-related death in the US and much of the world. The majority of cases are NSCLC, approximately 80%.
Etiology: Tobacco smoke is a known carcinogen to the lungs, and the most significant risk factor. Environmental substances also contribute including arsenic and asbestos.
Pathophysiology: Genetic lesions to bronchial epithelial cells lead to a variety of phenotypes each with specific treatment options
Lung Cancer4
NSCLC ~ 80% SCLC ~ 20%
Non-SquamousAdenocarcinoma/Large Cell
Squamous
Localized Regional Metastatic(Resectable: goal is to CURE with surgery, radiation, chemo)
(Not resectable: goal is to CURE with chemo-radiation + Durvalumab consolidation)
Stages & Chemotherapy
▹ Stage I▹ Stage II▹ Stage IIIa
For resected II and IIIa, chemotherapy may includeCisplatinOr +Carboplatin(for pts with CKD or HF)
5
VinorelbineEtoposideGemcitabineDocetaxilPemetrexed (Nonsquamous)
Nephrotoxicity with Cisplatin and Carboplatin6
Monitor for signs:● Decreased urine output (>125 mL/h)● Increased SCr● Decreased Mg & K
Oxaliplatin has the lowest risk of nephrotoxicity
Stages &
▹ Stage IVTARGETS: FIRST-LINE-inibs:EGFR - OsimertinibALK - AlectinibROS1 - CrizotinibBRAF - Dabrafenib + TramNTRK - Larotrec
PD-L1 Expression...
7
VinorelbineEtoposideGemcitabineDocetaxilPemetrexed (Nonsquamous)
PD-L1 First-line therapy8
Pembrolizumab (Keytruda) has been shown to be of equal efficacy to chemotherapy in patients with PD-L1 TPS >1% with a much more benign SE profile
MaintenanceTherapy for metastatic NSCLC
PD-L1 >1%Pembrolizumab 1st line▹ After 4-6 cycles, assessed
for a response. Maintenance tx includes▸ Continuation, switch,
observation
Targeted(EGFR, ALK, ROS, BRAF, NTRK)▹ Continue therapy
until progression
9
Sick of Keytruda?Looking for the best immune-checkpoint inhibitor in NSCLC patients?
10
Patient population: NSCLC w/ PD-L1 expressionIntervention: PembrolizumabComparator: Other immune checkpoint inhibitorsOutcome: Survival
Selecting the evidence:
Search results:52 peer-reviewed articles were located, including new clinical trials, systematic reviews, and meta-analyses.
Form of literature:We will choose a meta-analysis given the volume of trials to be evaluated, and offer the broadest view of potential treatment options
11
Picking a paper:Four such studies match our specific criteria, two were excluded for not comparing individual immune-checkpoint inhibitors
”
“Nivolumab versus pembrolizumab. The results of our analysis did not show any significant differences in the efficacy endpoints (ORR, PFS, OS) between these two
anti-PD1inhibitors, even if considering only the PD–L11 population. Nivolumab was associated with a significant
reduction of G3/G5 AEs (RR 0.41, 95% CI 0.29–0.60)”
12
Looking for the best immune-checkpoint inhibitor in NSCLC patients?
Passiglia F, Galvano A, Rizzo S, et al. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab. Int J Cancer. 2018;142(6):1277-1284.
”
“DISCUSSION: ICIs improve survival in previously treated advanced NSCLC patients across PD-L1 expression levels compared to docetaxel. There is a positive dose-response
relationship between PD-L1 expression and survival benefits, and little evidence of survival differences between
nivolumab, pembrolizumab and atezolizumab.”
13
Any differences at all when comparing their effectiveness?
Tan PS, Aguiar P, Haaland B, Lopes G. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants. Lung Cancer. 2018;115:84-88.
Decision pointWeighing the benefits and risks, expenses and availability, pharmacists are qualified to recommend the most appropriate choice of therapy, contingent that the patient needs come first.
14 $
Questions?
References:
▹ National Comprehensive Cancer Network. Non-small Cell Lung Cancer. http://www.nccn.org/professionals/physician_gls/pdf/nsclc.pdf. Accessed October 15, 2019
▹ Passiglia F, Galvano A, Rizzo S, et al. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab. Int J Cancer. 2018;142(6):1277-1284.
▹ Tan PS, Aguiar P, Haaland B, Lopes G. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants. Lung Cancer. 2018;115:84-88.
▹ DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995 - . Record No. T114774, Non-small Cell Lung Cancer; [updated 2018 Dec 04, cited place cited date here]. Available from https://www-dynamed-com.ezproxymcp.flo.org/topics/dmp~AN~T114774. Registration and login required.
▹ DiPiro, Joseph T. Pharmacotherapy-- a Pathophysiologic Approach. McGraw-Hill Education, 2017.
16